Not medical advice. Talk to your provider before using any peptide.
Full disclaimer
CortexinSmall moleculeNo amino acid sequence. Icon reflects category theme only.Also known as: Cortexin, Кортексин (Russian)
A multicenter randomized double-blind placebo-controlled trial across 189 patients confirmed that adding Cortexin to standard stroke therapy improves neurological deficit scores and functional recovery at 30 days [1]. This bovine/porcine cerebral cortex extract contains standardized neuropeptides under 10 kDa, along with L-glycine, vitamins, and trace minerals. It's been approved in Russia since 1999 and prescribed across CIS countries for stroke, TBI, and cognitive decline. The catch: over 200 published studies exist, but almost all are Russian-language, and no FDA-equivalent approval exists anywhere outside the CIS region. Community users run 10-day IM courses 2 to 3 times per year for subtle, delayed-onset cognitive gains.
Over 200 published studies and 25+ years of clinical use across Russia and CIS countries. That's the evidence base behind Cortexin, a lyophilized polypeptide fraction extracted from the cerebral cortex of young cattle or pigs through acid extraction and purification at the Institute of Bioregulation and Gerontology in St. Petersburg. The preparation belongs to the Khavinson peptide bioregulator class. Short-chain peptides under 10 kDa cross neuronal membranes and interact with chromatin, restoring expression of neurotrophic factors like BDNF and NGF. The result is a dual action: neuroprotection during acute injury plus longer-term neuroplasticity support through gene regulation. Clinical applications span ischemic stroke, traumatic brain injury, chronic cerebrovascular insufficiency, and pediatric neurodevelopmental conditions. The strongest data comes from a 189-patient multicenter RCT [1] that showed improved NIHSS scores and functional recovery at 30 days when Cortexin was added to standard stroke therapy. A separate RCT (n=189)[2] confirmed dose-dependent benefits at 20 mg/day with safety equivalent to 10 mg/day. In the community, Cortexin occupies a quiet niche. Reddit mentions total roughly 20 to 40 threads. Users who try it consistently describe the same pattern: minimal subjective effects during the 10-day injection course, with cognitive clarity, improved memory consolidation, and mild anxiolytic quality emerging 1 to 4 weeks after the last injection. A meaningful minority reports zero effect. Sourcing is the practical barrier; authentic GEROPHARM product requires cold-chain shipping from Russian-market vendors like CosmicNootropic or RuPharma. A 2022 Western meta-analysis [3] rated the overall evidence certainty as low to very low.
Cortexin operates through multiple pathways because it's a polypeptide complex, not a single molecule. The primary mechanism centers on tissue-specific bioregulation at the genomic level. Short-chain peptides in the 1 to 10 kDa range cross cell membranes and interact with promoter regions of genes encoding BDNF and NGF. This upregulation of neurotrophin expression promotes neuronal survival, synaptic plasticity, and axonal regeneration. At the receptor level, Cortexin shifts the balance between glutamatergic excitation and GABAergic inhibition. Under ischemic conditions, it reduces pathological glutamate release and attenuates NMDA receptor-mediated calcium influx. That limits excitotoxic neuronal death, the primary cause of irreversible damage during stroke. Electrophysiological studies confirm normalization of cortical bioelectrical activity and improved interhemispheric coherence on EEG. Direct antioxidant properties round out the profile. Cortexin scavenges reactive oxygen species and boosts endogenous antioxidant enzymes including superoxide dismutase and glutathione peroxidase. Lipid peroxidation in neuronal membranes drops, preserving membrane integrity during oxidative stress. Additional downstream effects include stabilization of mitochondrial membrane potential, caspase-3 downregulation (reducing apoptotic signaling), and modulation of IL-1beta and TNF-alpha in injured tissue.
Cortexin demonstrates consistent neurological benefit vs. placebo in Russian RCTs for ischemic stroke and TBI. Evidence base is large (200+ papers) but predominantly Russian-language with limited independent replication. Best evidence is in acute stroke (multicenter RCT, n=189)[1] and chronic cerebral ischemia.
PMID 29652367: multicenter randomized double-blind placebo-controlled trial of Cortexin in acute ischemic stroke; confirmed improved neurological deficit scores and functional recovery at 30 days.
Predominantly Russian-language literature; minimal independent Western replication; polypeptide complex (not single molecule) limits PK/PD characterization; evidence certainty rated low-to-very-low in the only Western meta-analysis (PMID 36324709).
Community rates Cortexin as a subtle, delayed-onset cognitive enhancer rather than an acute nootropic. Responder rate is variable: a meaningful minority reports no effect. Most prized for post-TBI recovery and general neuroplasticity rather than performance optimization.
Science and community agree on 10 mg/day × 10-day IM course and delayed-onset timeline. Science focuses on neurological rehabilitation (stroke, TBI) while community uses it primarily for cognitive enhancement in healthy individuals: an extrapolation beyond the validated clinical population. Community confidence in effects is weaker than the clinical trial data would suggest.
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 5mg | Daily |
| Moderate | 10mg | Daily |
| Aggressive | 10mg | 2x Daily |
Cortexin ships as a lyophilized powder in 5 mg or 10 mg vials. You'll reconstitute each vial with 1 to 2 mL of sterile water for injection right before use. Don't store the reconstituted solution; use it immediately. For a 10 mg vial reconstituted with 1 mL sterile water: you get 10 mg/mL concentration. Draw up 100 units (the full 1.0 mL) on a U100 insulin syringe for a 10 mg dose. For the 5 mg beginner dose from a 10 mg vial, draw 50 units (0.5 mL). For a 5 mg vial with 1 mL water, the full syringe is your dose. The non-obvious thing most beginners miss: you won't feel much during the 10-day course. Peak effects show up 1 to 4 weeks after the last injection. Evaluating at Day 10 is the single most common mistake; give it a full month before judging. If the injection hurts, switch your diluent from sterile water to 0.5% procaine solution (unless you have a local anesthetic allergy). Deep IM injection into deltoid or gluteal muscle, rotated daily, minimizes site reactions. Cold-chain matters; inspect the powder on arrival. It should be white to off-white. Discard if discolored, clumped, or if the vial seal is broken.
Standard Russian protocol: 10-day treatment course (daily IM injections), repeated 2-4 times per year with at least 3-month intervals between courses. Acute conditions may use two courses back-to-back with a 10-day break.
Cortexin cycling follows a pulsed bioregulatory model: a 10-day injection course triggers a wave of BDNF/NGF gene expression and neurotrophic factor release that continues and matures for 4–8 weeks post-course. The 3-month minimum interval allows the full neurotrophic response to consolidate before the next stimulation. Running courses more frequently is not validated and may produce diminishing returns as the gene regulatory pathway requires recovery time. The interval also allows detection of any delayed adverse reactions and practical monitoring of cumulative benefit.
Or use the universal Peptide Calculator for any peptide.
Expected: Measurable improvement in neurological deficit scores by Day 8–10; continued functional improvement for 4–8 weeks post-course as neurotrophic changes mature.
Monitor: No routine labs required. Observe for injection site reactions and allergic response (animal-derived product). In stroke/TBI patients, track neurological deficit scales (NIHSS, mRS) at Day 10 and 30-day follow-up.
Remove one Cortexin vial (10 mg) from refrigerator storage (2 to 8 degrees C). Allow to reach room temperature for 2 to 3 minutes. Inspect the lyophilized powder; it should be white to off-white with no discoloration or clumping.
Using a 3 mL syringe with a drawing needle (18 to 21 gauge), draw 1 mL of sterile water for injection or 0.5% procaine solution. Inject the diluent slowly down the side of the vial. Gently swirl until fully dissolved. Do not shake.
Draw the full 100 units (1.0 mL) from the vial. This equals your 10 mg dose. For a 5 mg dose from a 5 mg vial reconstituted with 1 mL, draw the full 100 units.
Choose your injection site: deltoid (upper arm) or gluteal muscle (upper outer quadrant of the buttock). Clean the area with an alcohol swab.
Inject slowly over 1 to 2 minutes. Slow injection reduces pain and improves absorption.
Withdraw the needle, apply gentle pressure with a cotton pad. Rotate injection sites daily across the 10-day course.
Morning timing is preferred to avoid potential sleep disturbances. Repeat the 10-day course every 3 to 6 months.
Do not store or reuse.
Pediatric dosing: children under 20 kg receive 0.5 mg/kg/day, not exceeding 10 mg total.
Most common Cortexin combination in Russian clinical neurology and the Western community. Complementary neuropeptide complexes: Cerebrolysin (whole-brain porcine extract) and Cortexin (cortex-specific bovine/porcine extract) are believed to have additive neurotrophic effects. Both run as 10-day IM courses, often simultaneously.
10 mg Cortexin IM + Cerebrolysin 5–10 mL IM/IV daily × 10 days
Semax (synthetic ACTH analogue, nasal or SC) provides acute cognitive activation while Cortexin provides sustained neurotrophic baseline support. Stack used in the community for general cognitive enhancement; Semax is taken daily, Cortexin in 10-day courses.
Semax 300–600 mcg intranasal daily during and after Cortexin course
Selank (anxiolytic/nootropic tetrapeptide) combined with Cortexin for anxiety reduction alongside neuroprotection. Community reports synergistic anxiolytic + neuroplasticity benefit. Selank is taken daily, Cortexin in 10-day courses.
Selank 300 mcg intranasal BID during and after Cortexin course
Both are Khavinson-class peptide bioregulators. Pinealon (EDR tripeptide, pineal-specific) + Cortexin (cortex neuropeptides) stacked for broader bioregulatory coverage. Seen in Khavinson Institute multi-bioregulator protocols.
Additive neurostimulatory effects possible when stacking multiple neuropeptide complexes simultaneously. No formal interaction data exists. Running Cortexin and Cerebrolysin at the same time is common practice, but adding a third CNS-active peptide complex (e.g., Selank + Semax + Cortexin + Cerebrolysin all at once) increases monitoring complexity without validated safety data.
Cortexin is sometimes reconstituted with 0.5% procaine to reduce injection pain. Contraindicated in patients with known allergy to local anesthetics (procaine, lidocaine, amide-class). Use sterile water for injection as the safe default diluent.
Do not combinePricing updated 2026-04-09
Prion-related concerns get the most attention from Western users, so start there. Cortexin is derived from bovine or porcine cerebral cortex tissue. The preparation's strict molecular weight cutoff (under 10 kDa) excludes prion-sized proteins, and no prion transmission cases have been documented in 25+ years of clinical use across millions of treatment courses in Russia and CIS countries. The risk is theoretical but not zero, and it's the primary hesitancy factor for users outside the CIS region. Allergic reactions are the most clinically relevant safety concern. Because the preparation contains animal-derived proteins, hypersensitivity responses including local urticaria and skin rash have been reported, primarily in patients with known sensitivity to bovine or porcine proteins. Anaphylaxis is rare but possible. Individuals with severe allergy history to bovine or porcine proteins should not use Cortexin. Injection site pain is common with IM administration. Reconstituting with 0.5% procaine (novocaine) solution instead of sterile water reduces this substantially, but procaine carries its own contraindication: patients with known allergy to local anesthetics (procaine, lidocaine, amide-class) must use sterile water only. Psychomotor agitation and sleep disturbances occur during the first few days of some treatment courses. These are transient and self-resolving, typically clearing by Day 4 to 5. Moving the injection to morning administration prevents most sleep disruption. Transient headache and dizziness shortly after administration are the most commonly noted side effects in clinical literature. Adverse event rates in RCTs were comparable to placebo. Pregnancy and breastfeeding: insufficient safety data exists. This is a contraindication. Known hypersensitivity to Cortexin, glycine, or other excipients is also a hard stop. When to stop: any sign of allergic reaction (rash, urticaria, facial swelling, respiratory distress). When to see a doctor: anaphylactic symptoms, persistent injection site infection, or psychomotor agitation that doesn't resolve after Day 3 to 4 of a course.
Verify Cortexin dosing and safety with a second opinion
Cortexin is an animal-derived polypeptide complex requiring rigorous cold-chain maintenance. The authentic Russian product (GEROPHARM, St. Petersburg) is pharmaceutical-grade and well-standardized. Risk arises from: (1) cold-chain integrity during gray-market shipping; (2) difficulty authenticating product source outside Russia; (3) theoretical (unconfirmed) prion risk from bovine/porcine CNS tissue: mitigated by <10 kDa molecular weight cutoff that excludes prion-sized proteins.
| Test | When | Target |
|---|---|---|
| Neurological deficit assessment (NIHSS, mRS, or MMSE) | Baseline before course; Day 10; 30-day post-course | Reduction in NIHSS score; improvement in mRS toward 0–2; MMSE improvement of ≥2 points in cognitive decline |
| Allergy/hypersensitivity observation | After first injection and first 3 injections of any new batch | No injection site reaction beyond mild transient erythema |
Primary efficacy endpoint in clinical trials. Tracks neurological improvement in stroke/TBI use case.
Animal-derived protein complex with theoretical immunogenicity. Allergic reactions (urticaria, local rash) documented rarely.
Minimal noticeable effects. Some patients report mild psychomotor activation or slight headache as the polypeptide complex begins to act.
Gradual improvements in mental clarity, attention, and alertness. Stroke patients may begin showing measurable improvements on neurological deficit scales.
Peak benefits of the treatment course. Improved cognitive function, better EEG patterns, and continued neurological recovery in stroke and TBI patients.
Effects persist and may continue to improve after the injection course ends due to ongoing gene expression changes and neurotrophic factor upregulation.
Cumulative benefits with repeated treatment courses. Clinical studies show progressive improvement with each successive 10-day course over a 12-month period.
Days 1 to 3: Largely uneventful. The polypeptide complex begins interacting with neuronal gene promoters; BDNF and NGF upregulation starts at the molecular level, but nothing measurable happens yet. Some users report very mild alertness or a slight headache on Day 1 or 2. Injection site pain and transient dizziness are possible. Psychomotor agitation occurs in some users but typically self-resolves. Days 4 to 7: Subtle shifts begin. Clinical patients may show measurable NIHSS improvement at this stage. Community users describe gradually improving mental clarity, better attention, and a sense of alertness that's hard to pin down. EEG bioelectrical activity begins normalizing in monitored patients. Nothing dramatic. Days 8 to 10: The course ends here. Clinical studies show peak measurable changes on neurological deficit scales. BDNF and NGF upregulation reaches its maximum. But here's the counterintuitive part: most community users still don't feel a clear subjective difference at this point. That comes next. Weeks 1 to 4 post-course: This is the real effect window. Neurotrophic factor changes continue expressing after the last injection. Synaptic plasticity and axonal regeneration keep building. Community users consistently report peak subjective effects during this phase: sharper memory consolidation, clearer thinking, and a mild anxiolytic quality. The effects are described as subtle but distinct from baseline. Months 2 to 3 (inter-course interval): Benefits persist but gradually fade over 6 to 10 weeks. Clinical studies show progressive improvement with each successive course across a 12-month period. Most users schedule their next course around the 3-month mark, matching the established Russian clinical protocol.
Polypeptide complex begins interacting with neuronal gene promoters; BDNF/NGF upregulation initiates. No measurable functional changes at this stage.
Largely uneventful. Some users report very mild alertness or slight headache on Day 1–2.
Gradual improvements in EEG bioelectrical activity and neurological deficit scores in clinical patients. BDNF/NGF levels rising. Antioxidant and anti-excitotoxic effects ongoing.
Subtle improvements in mental clarity, attention, and alertness noted by responsive users. No dramatic effect.
Peak measurable changes on neurological deficit scales in RCTs. Normalization of cortical bioelectrical activity on EEG. Maximum BDNF/NGF upregulation achieved.
Most users still not feeling a clear subjective effect at Day 10. Course ends here.
Neurotrophic factor changes continue to express after the injection course ends; synaptic plasticity and axonal regeneration processes ongoing. Functional recovery continues in clinical patients.
Most users report peak subjective effects here: memory consolidation, cognitive clarity, mild anxiolytic quality. Effects described as subtle but distinct from baseline.
Persistent but gradually fading neurotrophic benefit. Clinical studies show progressive improvement with each successive course over a 12-month period.
Effects fade gradually over 6–10 weeks post-course. Most users schedule the next course at 3 months.
Source: Estimated from polypeptide fraction kinetics; individual component PK not fully characterized (Skoromets et al., 2018)
Loading the interactive decay curve.
Cortexin has been registered and approved in the Russian Federation since 1999 for a range of neurological indications including ischemic stroke, traumatic brain injury, and cognitive disorders. It holds pharmaceutical registration across multiple CIS countries. No FDA approval exists. Cortexin has not been submitted for regulatory review in the United States, EU, UK, or any Western regulatory jurisdiction. It is classified as a research compound outside the CIS region. Import for personal use exists in a gray area; customs enforcement varies by country. For athletes: no specific WADA classification exists for Cortexin, but animal-derived peptide preparations may trigger complications under WADA's S0 category (non-approved substances). Competition-tested athletes should verify current WADA guidance before use. Sourcing: authentic GEROPHARM-manufactured Cortexin is available through international vendors including CosmicNootropic and RuPharma. Verify holographic security labels and Russian-language regulatory markings. Avoid unbranded product from unverified suppliers. This content is for informational and research purposes only. It does not constitute medical advice, diagnosis, or treatment. Consult a qualified healthcare provider before using any peptide product.
Peptide Schedule Research TeamReviewed Apr 20268 Citations
